MedPath

Ciclesonide

Generic Name
Ciclesonide
Brand Names
Alvesco, Omnaris, Zetonna
Drug Type
Small Molecule
Chemical Formula
C32H44O7
CAS Number
126544-47-6
Unique Ingredient Identifier
S59502J185
Background

Ciclesonide is a glucocorticoid used to treat obstructive airway diseases. It is marketed under the brand name Alvesco.

Indication

For the treatment of nasal symptoms associated with seasonal and perennial allergic rhinitis in adults and adolescents 12 years of age and older.

Associated Conditions
Asthma, Bronchoconstriction, Chronic Obstructive Pulmonary Disease (COPD), Perennial Allergic Rhinitis (PAR), Seasonal Allergic Rhinitis
Clinical Trials
Related News

Efficacy and Safety Comparison of Steroid or Placebo in Combination With Salmeterol and Tiotropium in COPD

Phase 2
Completed
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Drug: Placebo
First Posted Date
2007-09-26
Last Posted Date
2014-05-30
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
103
Registration Number
NCT00535366
Locations
🇧🇪

1249.1.32002 Boehringer Ingelheim Investigational Site, Hasselt, Belgium

🇧🇪

1249.1.32001 Boehringer Ingelheim Investigational Site, Gent, Belgium

🇳🇱

1249.1.31003 Boehringer Ingelheim Investigational Site, Harderwijk, Netherlands

and more 9 locations

Effect of Ciclesonide on Exercise Induced Bronchoconstriction

Phase 3
Completed
Conditions
Asthma
Interventions
First Posted Date
2007-09-06
Last Posted Date
2009-10-21
Lead Sponsor
Hamilton Health Sciences Corporation
Target Recruit Count
26
Registration Number
NCT00525772
Locations
🇨🇦

McMaster University Medical Centre, Hamilton, Ontario, Canada

Comparison Between Systemic Exposure to Ciclesonide Nasal Spray, Ciclesonide HFA Nasal Aerosol and Orally Inhaled Ciclesonide (BY9010/M1-422)

Phase 4
Completed
Conditions
Allergic Rhinitis
Interventions
First Posted Date
2007-04-11
Last Posted Date
2023-02-09
Lead Sponsor
Covis Pharma S.à.r.l.
Target Recruit Count
30
Registration Number
NCT00458835
Locations
🇺🇸

ALTANA Pharma, Austin, Texas, United States

Asthma Care With Alvesco® (Ciclesonide) in Primary Care in Adults - The ACCEPT-study (BY9010/CA-102)

Phase 4
Completed
Conditions
Asthma
Interventions
Drug: Usual Care Inhaled Glucocorticosteroids
First Posted Date
2006-11-28
Last Posted Date
2017-02-01
Lead Sponsor
AstraZeneca
Target Recruit Count
1121
Registration Number
NCT00404547
Locations
🇨🇦

"Altana Pharma/Nycomed", York, Canada

Efficacy and Safety of Ciclesonide (CIC) Administered Twice Daily in Pediatric Patients With Asthma.

Phase 3
Completed
Conditions
Asthma
Interventions
Drug: Placebo
First Posted Date
2006-10-25
Last Posted Date
2017-02-01
Lead Sponsor
AstraZeneca
Target Recruit Count
528
Registration Number
NCT00392288
Locations
🇲🇽

Sanofi-Aventis, Mexico, Mexico

🇵🇱

sanofi-aventis Poland, Warszawa, Poland

🇭🇺

Sanofi-Aventis Hungaria, Budapest, Hungary

and more 3 locations

A Study of Ciclesonide Nasal Spray in Patients 18 Years and Older With Seasonal Allergic Rhinitis (BY9010/M1-413)

Phase 3
Completed
Conditions
Rhinitis, Allergic, Seasonal
Hay Fever
First Posted Date
2006-10-06
Last Posted Date
2016-11-30
Lead Sponsor
AstraZeneca
Target Recruit Count
500
Registration Number
NCT00384475
Locations
🇨🇦

Altana Pharma/Nycomed, Ontario, Mississauga, Canada

A Comparative Study of Inhaled Ciclesonide Versus Placebo in Children (6-11 Years) With Asthma

Phase 3
Completed
Conditions
Asthma
Interventions
Drug: Placebo
First Posted Date
2006-10-05
Last Posted Date
2017-02-01
Lead Sponsor
AstraZeneca
Target Recruit Count
1080
Registration Number
NCT00384189
Locations
🇺🇦

Altana Pharma/Nycomed, Zaporizhzhya, Ukraine

Evaluation of Traditional Paper Symptom Diary vs. the VOCEL Mobile Diary

Not Applicable
Completed
Conditions
Asthma
First Posted Date
2006-08-22
Last Posted Date
2007-05-02
Lead Sponsor
Allergy & Asthma Medical Group & Research Center
Target Recruit Count
12
Registration Number
NCT00367263
Locations
🇺🇸

Allergy & Asthma Medical Group & Research Center, San Diego, California, United States

Responsiveness of Lower Airways in Adult Patients (18-60 Years) With Stable Asthma After Treatment With Ciclesonide and Fluticasone Propionate (BY9010/NL-101)

Phase 3
Completed
Conditions
Asthma
Interventions
First Posted Date
2006-03-23
Last Posted Date
2017-02-01
Lead Sponsor
AstraZeneca
Target Recruit Count
37
Registration Number
NCT00306163
Locations
🇳🇱

Altana Pharma/Nycomed, RB Groningen, Netherlands

Effect of Ciclesonide on Quality of Life in Patients With Moderate Persistent Asthma (21 to 65 y) (BY9010/AR-101)

Phase 3
Completed
Conditions
Asthma
Interventions
First Posted Date
2006-03-22
Last Posted Date
2016-12-05
Lead Sponsor
AstraZeneca
Target Recruit Count
101
Registration Number
NCT00305461
Locations
🇦🇷

Altana Pharma/Nycomed, Tucuman, Argentina

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy